142752-12-3

Basic information

• Product Name: 1-(4-aminophenyl)piperidin-4-ol
• Synonyms: 1-(4-aminophenyl)piperidin-4-ol;1-(4-AMINOPHENYL)-4-HYDROXYPIPERIDINE;OTAVA-BB 1147946
• CAS NO: 142752-12-3
• Molecular Formula: C₁₁H₁₆N₂O
• Molecular Weight: 192.26
• Mol File: 142752-12-3.mol

Chemical Properties

• Melting Point: 158 °C
• Boiling Point: 404.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.194±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.88±0.20(Predicted)
• CAS DataBase Reference: 1-(4-aminophenyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-aminophenyl)piperidin-4-ol(142752-12-3)
• EPA Substance Registry System: 1-(4-aminophenyl)piperidin-4-ol(142752-12-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 142752-12-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
1-(4-aminophenyl)piperidin-4-ol is used as a research compound for understanding the structure-activity relationships in opioid analgesics. Its presence as a structural isomer of fentanyl allows scientists to explore the potential modifications and improvements in the design of opioid medications, aiming to enhance their efficacy and safety while minimizing side effects and addiction potential.
Used in Chemical Research:
1-(4-aminophenyl)piperidin-4-ol is used as a model compound in chemical research to study the reactivity and properties of piperidinol and aminophenyl functional groups. This can provide insights into the development of new synthetic methods, reaction mechanisms, and the creation of novel compounds with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.
Used in Drug Synthesis:
Although its specific applications are not well-documented, 1-(4-aminophenyl)piperidin-4-ol may be used as an intermediate in the synthesis of other opioid analgesics or related compounds. Its structural features could be exploited in the development of new drugs with improved pharmacological profiles, such as higher potency, better selectivity, or reduced side effects.

Upstream product

• 79421-45-7 4-(4-hydroxypiperidinyl)nitrobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 350-46-9 4-Fluoronitrobenzene 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 251371-45-6 1-Isopropyl-7-[4-(4-hydroxypiperidin-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 
• 251369-96-7 1-Methyl-7-[4-(4-hydroxypiperidin-1-yl)phenylamino]-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2(1H)-one 
• 1192708-56-7 1-(4-(4-(cyclobutylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperidin-4-ol 
• 1127364-90-2 N-(4-(2-(4-(4-hydroxypiperidin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)methanesulfonamide 
• 1244967-96-1 N-(4-(4-hydroxypiperidin-1-yl)-phenyl)-4-((1-methylpyrrol-2-yl)-carbonyl)-1-piperazinecarboxamide 
• 1415794-29-4 2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yloxy)ethanol 
• 1226154-84-2 1-(4-bromophenyl)piperidin-4-ol 
• 1415794-27-2 tert-butyl 2-(1-(4-bromophenyl)piperidin-4-yloxy)acetate 
• 1415794-28-3 2-(1-(4-bromophenyl)piperidin-4-yloxy)ethanol 
• 1122710-01-3 1-(4-(4-(1H-indazol-6-ylamino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperidin-4-ol 
• 119836-12-3 4-hydroxy-1-(4-chlorophenyl)piperidine 

Relevant articles and documents

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically advantageous, such behavior can also lead to toxicity and confound chemical-biology studies. We report a novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK. Structure-activity relationship (SAR) studies explored modifications to the thiazole, diazepinone, and aniline "tail,"which identified lead compound BJG-03-025. BJG-03-025 displays potent biochemical FAK inhibition (IC50 = 20 nM), excellent kinome selectivity, activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. BJG-03-025 is a valuable chemical probe for evaluation of FAK-dependent biology.

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

FGFR Inhibitor compounds and uses thereof

The invention relates to FGFR inhibitor compounds and uses thereof. , The application discloses a compound as shown in a formula (I). A compound, or an optical isomer, a geometric isomer, a tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The application further relates to the application of the compound in medicine.

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE

This invention relates to a piperazine compound represented by Formula (I), wherein R1 is C1-6 alkyl;R2 is hydroxy, C1-6 alkyl that may have one or more substituents, —(C═O)—N(R3)(R4), or —(C═O)—OR5;R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents, orR3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group;R5 is hydrogen or C1-6 alkyl that may have one or more substituents; andn is 1 or 2;or a salt thereof.